| Literature DB >> 34819174 |
Sueli Carneiro1, Penelope Esther Palominos2, Sônia Maria Alvarenga Anti3, Rodrigo Luppino Assad4, Rafaela Silva Guimarães Gonçalves5, Adriano Chiereghin6, Andre Marun Lyrio7, Antônio Carlos Ximenes8, Carla Gonçalves Saad9, Célio Roberto Gonçalves9, Charles Lubianca Kohem2, Cláudia Diniz Lopes Marques5, Cláudia Goldenstein Schainberg9, Eduardo de Souza Meirelles9, Gustavo Gomes Resende10, Lenise Brandao Pieruccetti11, Mauro Waldemar Keiserman12, Michel Alexandre Yazbek13, Percival Degrava Sampaio-Barros9, Ricardo da Cruz Lage10, Rubens Bonfiglioli7, Thauana Luíza Oliveira14, Valderílio Feijó Azevedo15, Washington Alves Bianchi16, Wanderley Marques Bernardo9, Ricardo Dos Santos Simões17, Marcelo de Medeiros Pinheiro14, Cristiano Barbosa Campanholo18.
Abstract
Psoriatic arthritis (PsA) is a chronic and systemic immune disease characterized by inflammation of peripheral and/or axial joints and entheses in patients with psoriasis (PsO). Extra-articular and extracutaneous manifestations and numerous comorbidities can also be present. These recommendations replace the previous version published in May 2013. A systematic review of the literature retrieved 191 articles that were used to formulate 12 recommendations in response to 12 clinical questions, divided into 4 sections: diagnosis, non-pharmacological treatment, conventional drug therapy and biologic therapy. These guidelines provide evidence-based information on the clinical management for PsA patients. For each recommendation, the level of evidence (highest available), degree of strength (Oxford) and degree of expert agreement (interrater reliability) are reported.Entities:
Keywords: Guideline; Inflammation; Psoriatic arthritis; Spondyloarthropathies; Treatment
Mesh：
Year: 2021 PMID： 34819174 DOI： 10.1186/s42358-021-00219-y
Source DB: PubMed Journal: Adv Rheumatol ISSN： 2523-3106